D
Asensus Surgical, Inc.
ASXC
AMEX
E
Sell
5/20/2024Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to E+ from D- on 5/20/2024 due to a noticeable decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.03 to 0.08, total revenue declined 79.32% from $5.43M to $1.12M, and the quick ratio declined from 1.95 to 0.45.
Asensus Surgical, Inc. (ASXC) was downgraded to E+ from D- on 5/20/2024 due to a noticeable decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.03 to 0.08, total revenue declined 79.32% from $5.43M to $1.12M, and the quick ratio declined from 1.95 to 0.45.
D
Sell
4/11/2024Upgraded
Asensus Surgical, Inc. (ASXC) was upgraded to D- from E+ on 4/11/2024 due to an increase in the total return index and volatility index.
Asensus Surgical, Inc. (ASXC) was upgraded to D- from E+ on 4/11/2024 due to an increase in the total return index and volatility index.
E
Sell
3/25/2024Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to E+ from D- on 3/25/2024 due to a decline in the solvency index and volatility index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 2.78 to 1.95.
Asensus Surgical, Inc. (ASXC) was downgraded to E+ from D- on 3/25/2024 due to a decline in the solvency index and volatility index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 2.78 to 1.95.
D
Sell
1/10/2024Upgraded
Asensus Surgical, Inc. (ASXC) was upgraded to D- from E+ on 1/10/2024 due to an increase in the total return index and volatility index.
Asensus Surgical, Inc. (ASXC) was upgraded to D- from E+ on 1/10/2024 due to an increase in the total return index and volatility index.
E
Sell
12/18/2023Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to E+ from D- on 12/18/2023 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 3.87 to 2.78.
Asensus Surgical, Inc. (ASXC) was downgraded to E+ from D- on 12/18/2023 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 3.87 to 2.78.
D
Sell
3/14/2023Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 9.12 to 7.04, and total revenue declined 3.86% from $2.56M to $2.46M.
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 9.12 to 7.04, and total revenue declined 3.86% from $2.56M to $2.46M.
D
Sell
2/23/2023Upgraded
Asensus Surgical, Inc. (ASXC) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Asensus Surgical, Inc. (ASXC) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 2/8/2023 due to a major decline in the solvency index and valuation index. The quick ratio declined from 9.92 to 9.12.
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 2/8/2023 due to a major decline in the solvency index and valuation index. The quick ratio declined from 9.92 to 9.12.
D
Sell
5/5/2022Upgraded
Asensus Surgical, Inc. (ASXC) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
Asensus Surgical, Inc. (ASXC) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 46.32% from -$9M to -$13.17M, the quick ratio declined from 12.74 to 10.2, and EBIT declined 6.42% from -$17.16M to -$18.26M.
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 46.32% from -$9M to -$13.17M, the quick ratio declined from 12.74 to 10.2, and EBIT declined 6.42% from -$17.16M to -$18.26M.
D
Sell
11/23/2021Upgraded
Asensus Surgical, Inc. (ASXC) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Asensus Surgical, Inc. (ASXC) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Earnings per share declined from -$0.0565 to -$0.0686, EBIT declined 9.96% from -$15.61M to -$17.16M, and operating cash flow declined 9.14% from -$8.25M to -$9M.
Asensus Surgical, Inc. (ASXC) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Earnings per share declined from -$0.0565 to -$0.0686, EBIT declined 9.96% from -$15.61M to -$17.16M, and operating cash flow declined 9.14% from -$8.25M to -$9M.
D
Sell
11/9/2020Upgraded
TransEnterix, Inc. (TRXC) was upgraded to D from D- on 11/9/2020 due to a significant increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.2701 to -$0.1546, operating cash flow increased 30.69% from -$12.66M to -$8.77M, and total revenue increased 24.27% from $655 to $814.
TransEnterix, Inc. (TRXC) was upgraded to D from D- on 11/9/2020 due to a significant increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.2701 to -$0.1546, operating cash flow increased 30.69% from -$12.66M to -$8.77M, and total revenue increased 24.27% from $655 to $814.
D
Sell
4/6/2020Upgraded
TransEnterix, Inc. (TRXC) was upgraded to D- from E+ on 4/6/2020 due to an increase in the volatility index.
TransEnterix, Inc. (TRXC) was upgraded to D- from E+ on 4/6/2020 due to an increase in the volatility index.
E
Sell
3/20/2020Downgrade
TransEnterix, Inc. (TRXC) was downgraded to E+ from D- on 3/20/2020 due to a decline in the growth index, total return index and volatility index. Total revenue declined 66.06% from $2.02M to $687, and EBIT declined 18.14% from -$22.66M to -$26.76M.
TransEnterix, Inc. (TRXC) was downgraded to E+ from D- on 3/20/2020 due to a decline in the growth index, total return index and volatility index. Total revenue declined 66.06% from $2.02M to $687, and EBIT declined 18.14% from -$22.66M to -$26.76M.
D
Sell
12/27/2019Upgraded
TransEnterix, Inc. (TRXC) was upgraded to D- from E+ on 12/27/2019 due to an increase in the valuation index.
TransEnterix, Inc. (TRXC) was upgraded to D- from E+ on 12/27/2019 due to an increase in the valuation index.
E
Sell
12/12/2019Downgrade
TransEnterix, Inc. (TRXC) was downgraded to E+ from D- on 12/12/2019 due to a substantial decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.1037 to -$0.4266, total revenue declined 44.38% from $3.64M to $2.02M, and operating cash flow declined 27.6% from -$15.34M to -$19.58M.
TransEnterix, Inc. (TRXC) was downgraded to E+ from D- on 12/12/2019 due to a substantial decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.1037 to -$0.4266, total revenue declined 44.38% from $3.64M to $2.02M, and operating cash flow declined 27.6% from -$15.34M to -$19.58M.
D
Sell
5/1/2019Downgrade
TransEnterix, Inc. (TRXC) was downgraded to D- from D on 5/1/2019 due to a noticeable decline in the solvency index, volatility index and total return index.
TransEnterix, Inc. (TRXC) was downgraded to D- from D on 5/1/2019 due to a noticeable decline in the solvency index, volatility index and total return index.
D
Sell
3/4/2019Upgraded
TransEnterix, Inc. (TRXC) was upgraded to D from D- on 3/4/2019 due to a substantial increase in the solvency index, growth index and total return index. Earnings per share increased from -$0.0966 to -$0.0299, total revenue increased 38.77% from $5.42M to $7.52M, and operating cash flow increased 21.88% from -$16.45M to -$12.85M.
TransEnterix, Inc. (TRXC) was upgraded to D from D- on 3/4/2019 due to a substantial increase in the solvency index, growth index and total return index. Earnings per share increased from -$0.0966 to -$0.0299, total revenue increased 38.77% from $5.42M to $7.52M, and operating cash flow increased 21.88% from -$16.45M to -$12.85M.
D
Sell
11/13/2017Downgrade
TransEnterix, Inc. (TRXC) was downgraded to D- from D on 11/13/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.1111 to -$0.26, total revenue declined 88.45% from $1.58M to $183, and the quick ratio declined from 1.91 to 1.34.
TransEnterix, Inc. (TRXC) was downgraded to D- from D on 11/13/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.1111 to -$0.26, total revenue declined 88.45% from $1.58M to $183, and the quick ratio declined from 1.91 to 1.34.
D
Sell
10/20/2017Upgraded
TransEnterix, Inc. (TRXC) was upgraded to D from on 10/20/2017 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.62 to 1.91, operating cash flow increased 17.08% from -$13.95M to -$11.57M, and EBIT increased 13.91% from -$14.65M to -$12.61M.
TransEnterix, Inc. (TRXC) was upgraded to D from on 10/20/2017 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.62 to 1.91, operating cash flow increased 17.08% from -$13.95M to -$11.57M, and EBIT increased 13.91% from -$14.65M to -$12.61M.
